You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

Article metrics

Article menu

Download PDFPDF

Inflammatory arthritis
Original research
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

 

Online download statistics by month:

Online download statistics by month: November 2022 to March 2024

AbstractFullPdf
Nov 202228126789
Dec 2022236233108
Jan 202315115268
Feb 202312712860
Mar 2023828048
Apr 2023686732
May 2023545347
Jun 2023656128
Jul 2023373627
Aug 2023414226
Sep 2023313113
Oct 2023373821
Nov 2023464631
Dec 2023383521
Jan 2024483735
Feb 2024343339
Mar 2024504870
Total14261387763